Dr. Ruan on Lenalidomide Plus Rituximab in MCL

Jia Ruan, MD, PhD
Published: Monday, Jan 08, 2018



Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

The 5-year follow-up and correlative analysis from a phase II multi-center study of lenalidomide plus rituximab as initial treatment for patients with MCL was presented at the 2017 ASH Annual Meeting.

Ruan says that the aim of this study was to explore potential chemotherapy-free options for this patient population.
 
SELECTED
LANGUAGE


Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

The 5-year follow-up and correlative analysis from a phase II multi-center study of lenalidomide plus rituximab as initial treatment for patients with MCL was presented at the 2017 ASH Annual Meeting.

Ruan says that the aim of this study was to explore potential chemotherapy-free options for this patient population.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x